MAXVAX Biotechnology Limited Liability Company clinical trial pipeline

3 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 2 with minor changes only.

1. Notable

   Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects…Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above

   Primary completion date changed from estimate of Dec 28, 2024 to Sep 1, 2025

   Also in this update: Trial completed

   MAXVAX Biotechnology Limited Liability Company·Phase 2· NCT05856084· Registry history of NCT05856084 on ClinicalTrials.gov (opens the registry)

   Updated Oct 15, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.